RARECYTE, INC.

Seattle, WA · Medtech · Private

Orion2 multiplex immunofluorescence imaging instrument for automated high-resolution analysis of tissue specimens with machine learning-guided image acquisition

Claim this profile

Follows are private to you and power your alerts

Updated · rarecyte.com

Sector
Medtech
Headquarters
Seattle, WA
Latest Form D
$13.2M, Jul 2023
Total capital
$83M
Federal grants
$3.2M
5 awards · 2015–2025
Rank in peer group#236 of 538
Private capital raised
$79.8M
5 Form D · last Jul 2023
39 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
35
5 pending · first 2018
Rank in peer group#4 of 538

Capital timeline

201520172019202120232025FEDERAL ↑EQUITY ↓Cumulative $83M$299K$224K$1.1M$848K$658K1st Form D$15.4M5th Form D$13.2M
201520172019202120232025FEDERAL ↑EQUITY ↓Cumulative $83M$299K$1.1M$848K$658K1st Form D$15.4M

Latest events

  • Federal grantHealth and Human S · Phase II · Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis$658K
  • Private capital raisedForm D · SEC · 5th filing$13.2M
  • Private capital raisedForm D · SEC · 4th filing$24M
  • Federal grantHealth and Human S · Phase II · Rapid highly multi-plexed immuno-profiling of solid tumors by SpectralEdge imaging$848K
  • Federal grantHealth and Human S · Phase II · Rapid highly multi-plexed immuno-profiling of solid tumors by SpectralEdge imaging$1.1M
  • Private capital raisedForm D · SEC · 3rd filing$22.2M
  • Private capital raisedForm D · SEC · 2nd filing$5M
  • Private capital raisedForm D · SEC · 1st filing$15.4M
Show 2 earlier federal awards
  • Federal grantHealth and Human S · Phase I · Highly Multiplexed Analysis of Solid Tumors and Liquid Tissues by Cyclic Immunofluorescence$224K
  • Federal grantHealth and Human S · Phase I · Direct visualization assay for detection of B. burgdorferi in early Lyme Disease$299K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

25months

from RARECYTE, INC.’s first federal award to its first private round.

First federal award · Jul 2015
Health and Human S · $299K
First Form D · Aug 2017
$15.4M · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 538 peers

Line = median

Medtech · Device

  • Federal grants#236 · top 44%
  • Granted patents#4 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Eric KaldjianResearcherExecutive OfficerLinked by $2.5M in grants as PI
  • Andrew J. SchwabDirectorNamed in SEC Form D filings
  • Brian DanielsDirectorNamed in SEC Form D filings
  • Daniel J. MarshakDirectorNamed in SEC Form D filings
  • David J. KabakoffDirectorNamed in SEC Form D filings
  • Evan CastigliaExecutive OfficerNamed in SEC Form D filings
Show all 15 people
  • Frank J. WitneyDirectorNamed in SEC Form D filings
  • Jan J. GarfinkleDirectorNamed in SEC Form D filings
  • Jim J. CooperExecutive OfficerNamed in SEC Form D filings
  • Joseph VictorExecutive Officer, DirectorNamed in SEC Form D filings
  • Joseph J. Victor Jr.Executive Officer, DirectorNamed in SEC Form D filings
  • Robert SheplerDirectorNamed in SEC Form D filings
  • Robert J. WeisskoffDirectorNamed in SEC Form D filings
  • Ronald J. SeubertDirectorNamed in SEC Form D filings
  • Stephen J. ReichenbachExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 35 granted of 40
Show all 40 patent records

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .